A Brief Epidemiologic Review of Psoriasis

Psoriasis is an intricate, long-lasting, immune-mediated inflammatory skin condition that has a genetic origin. The body is affected to varying degrees; it can affect almost the entire body or just a few isolated red, scaly plaques. Psoriatic lesions may remain unchanged for years, growing, decreasi...

Full description

Saved in:
Bibliographic Details
Main Authors: Nagham Shaheed Mahmood, Rabab Omran, Anwar A. Abdulla
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2024-12-01
Series:Medical Journal of Babylon
Subjects:
Online Access:https://doi.org/10.4103/MJBL.MJBL_12_24
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841525509440143360
author Nagham Shaheed Mahmood
Rabab Omran
Anwar A. Abdulla
author_facet Nagham Shaheed Mahmood
Rabab Omran
Anwar A. Abdulla
author_sort Nagham Shaheed Mahmood
collection DOAJ
description Psoriasis is an intricate, long-lasting, immune-mediated inflammatory skin condition that has a genetic origin. The body is affected to varying degrees; it can affect almost the entire body or just a few isolated red, scaly plaques. Psoriatic lesions may remain unchanged for years, growing, decreasing, and regressing over time. As the patient ages, the condition could develop worse or “wax and wane” in intensity. Indeed, examples of primary skin lesions are pustules, macules, papules, and plaques. Psoriasis, however, tends to affect more than just the skin and nails; it can cause inflammatory arthritis and inflammatory bowel disease. Additionally, patients’ symptoms may vary greatly from one another. Skin appearances can manifest at any age and can be either monomorphic or polymorphic. Furthermore, numerous emotionally charged, stressful physiological and psychological events, systemic infections, and environmental factors are associated with the beginning and worsening of the condition. The underlying patho-mechanisms involve complex interactions between the innate and adaptive immune systems. T cells interact with dendritic cells, macrophages, and keratinocytes, which their secreted cytokines can mediate. Biologics targeting tumor necrosis factor, interleukin IL-23, and IL-17 have been developed and approved for treating psoriasis in the past decade. These biologics have dramatically changed the treatment and management of psoriasis.
format Article
id doaj-art-0482647491f2478193163b575afbb5a5
institution Kabale University
issn 1812-156X
2312-6760
language English
publishDate 2024-12-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Medical Journal of Babylon
spelling doaj-art-0482647491f2478193163b575afbb5a52025-01-17T10:54:56ZengWolters Kluwer Medknow PublicationsMedical Journal of Babylon1812-156X2312-67602024-12-0121475776510.4103/MJBL.MJBL_12_24A Brief Epidemiologic Review of PsoriasisNagham Shaheed MahmoodRabab OmranAnwar A. AbdullaPsoriasis is an intricate, long-lasting, immune-mediated inflammatory skin condition that has a genetic origin. The body is affected to varying degrees; it can affect almost the entire body or just a few isolated red, scaly plaques. Psoriatic lesions may remain unchanged for years, growing, decreasing, and regressing over time. As the patient ages, the condition could develop worse or “wax and wane” in intensity. Indeed, examples of primary skin lesions are pustules, macules, papules, and plaques. Psoriasis, however, tends to affect more than just the skin and nails; it can cause inflammatory arthritis and inflammatory bowel disease. Additionally, patients’ symptoms may vary greatly from one another. Skin appearances can manifest at any age and can be either monomorphic or polymorphic. Furthermore, numerous emotionally charged, stressful physiological and psychological events, systemic infections, and environmental factors are associated with the beginning and worsening of the condition. The underlying patho-mechanisms involve complex interactions between the innate and adaptive immune systems. T cells interact with dendritic cells, macrophages, and keratinocytes, which their secreted cytokines can mediate. Biologics targeting tumor necrosis factor, interleukin IL-23, and IL-17 have been developed and approved for treating psoriasis in the past decade. These biologics have dramatically changed the treatment and management of psoriasis.https://doi.org/10.4103/MJBL.MJBL_12_24decompression sickness (dcs)diagnosisepidemiologyetiologyhigh-frequency ultrasound (hfus)human immunodeficiency virus (hiv)psoriasispsoriasis area and severity index (pasi) score
spellingShingle Nagham Shaheed Mahmood
Rabab Omran
Anwar A. Abdulla
A Brief Epidemiologic Review of Psoriasis
Medical Journal of Babylon
decompression sickness (dcs)
diagnosis
epidemiology
etiology
high-frequency ultrasound (hfus)
human immunodeficiency virus (hiv)
psoriasis
psoriasis area and severity index (pasi) score
title A Brief Epidemiologic Review of Psoriasis
title_full A Brief Epidemiologic Review of Psoriasis
title_fullStr A Brief Epidemiologic Review of Psoriasis
title_full_unstemmed A Brief Epidemiologic Review of Psoriasis
title_short A Brief Epidemiologic Review of Psoriasis
title_sort brief epidemiologic review of psoriasis
topic decompression sickness (dcs)
diagnosis
epidemiology
etiology
high-frequency ultrasound (hfus)
human immunodeficiency virus (hiv)
psoriasis
psoriasis area and severity index (pasi) score
url https://doi.org/10.4103/MJBL.MJBL_12_24
work_keys_str_mv AT naghamshaheedmahmood abriefepidemiologicreviewofpsoriasis
AT rababomran abriefepidemiologicreviewofpsoriasis
AT anwaraabdulla abriefepidemiologicreviewofpsoriasis
AT naghamshaheedmahmood briefepidemiologicreviewofpsoriasis
AT rababomran briefepidemiologicreviewofpsoriasis
AT anwaraabdulla briefepidemiologicreviewofpsoriasis